68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies

68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies

As an emerging molecule targeting FAP, 68Ga-FAP-CHX is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAP-CHX in patients with various types of cancer and compared them with the results of 68Ga-FAPI-04 or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAP-CHX.

Fibroblast activation protein (FAP) is highly expressed in the stroma of a variety of human cancers and is therefore considered promising for guiding targeted therapy. The recent development of quinoline-based PET tracers that act as FAP inhibitors (FAPIs) demonstrated promising results preclinically and already in a few clinical cases. 68Ga-FAP-CHX is a novel FAP-targeted tracers. The present study aimed to evaluate the biodistribution, pharmacokinetics, and dosimetry of 68Ga-FAP-CHX, and performed a head-to-head comparison with 68Ga-FAPI-04 or 18F-FDG PET/CT scans in patients with various cancers.

Inclusion Criteria:

• 18 years < Age < 75 years
• Various solid tumors with available histopathological findings, and have not been treated surgically.
• Signed informed consent.

Exclusion Criteria:

• patients with pregnancy
• the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.